BioSight
Companies
Monte Rosa Therapeutics, Inc. logo

GLUE

NASDAQBOSTON, MA
Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics develops molecular glue degrader drugs designed to target proteins previously considered difficult or impossible to drug. The company is in early-stage development, with programs including MRT-2359 (targeting GSPT1), MRT-8102 (targeting NEK7), and MRT-6160 (targeting VAV1, out-licensed to Novartis), supported by its proprietary QuEEN discovery platform. Monte Rosa has partnered with Novartis to advance certain programs and is preparing to file investigational new drug applications with the FDA.

Price history not yet available for GLUE.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar